Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $55.38.

Several brokerages recently issued reports on CLDX. UBS Group began coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. The Goldman Sachs Group cut their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after buying an additional 1,167,659 shares during the period. Vanguard Group Inc. grew its stake in shares of Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock valued at $98,098,000 after buying an additional 12,213 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after buying an additional 676,771 shares during the period. Bellevue Group AG grew its stake in shares of Celldex Therapeutics by 3.4% during the 3rd quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after buying an additional 100,000 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock valued at $63,579,000 after buying an additional 847,264 shares during the period.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $20.35 on Thursday. The business’s 50 day simple moving average is $22.73 and its 200-day simple moving average is $27.65. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.92 and a beta of 1.76. Celldex Therapeutics has a 12 month low of $18.61 and a 12 month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. On average, equities analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.